Atara Biotherapeutics (ATRA) Retained Earnings (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Retained Earnings for 14 consecutive years, with -$2.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 0.83% year-over-year to -$2.0 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.0 billion (down 0.83% YoY), and the FY2025 full-year result was -$2.0 billion, up 1.59% from the prior year.
• Retained Earnings held at -$2.0 billion in Q2 2026 per ATRA's latest filing, from -$2.0 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$1.5 billion in Q2 2022 and bottomed at -$2.1 billion in Q4 2024.
• Historically, Retained Earnings has averaged -$1.9 billion across 5 years, with a median of -$2.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings decreased 29.09% in 2022, then advanced 1.59% in 2025.
• Over 5 years, Retained Earnings stood at -$1.7 billion in 2022, then dropped by 16.31% to -$2.0 billion in 2023, then fell by 4.34% to -$2.1 billion in 2024, then rose by 1.59% to -$2.0 billion in 2025, then dropped by 0.44% to -$2.0 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$2.0 billion, -$2.0 billion, and -$2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.